Medical Advocates
Pegylated Interferon alfa-2b (PEG-INTRON)
    Hepatic Disease Data

New and Noteworthy
Journal Papers, Abstracts, and Commentaries
Conference Reports, Abstracts, and Posters




 		  
HCV Drugs   Main New/Newsworthy Home Page

Last Update:  February 08, 2016

New and Noteworthy
     
February 2016
 
Journal Papers, Abstracts, and Commentaries
 

HCV Infection Disease


     Pharmacokinetics

  Viral dynamics and pharmacokinetics in combined interferon alfa-2b and ribavirin therapy for patientsinfected with hepatitis C virus of genotype 1b and high pretreatment viral load.
 Tsubota A, Akuta N, Suzuki F, et al.
 Intervirology 2002;45(1):33-42
 Abstract

     Viral Dynamics

 
Hepatitis C virus kinetics during the first phase of pegylated interferon-alpha-2b with ribavirin therapy in patients with living donor liver transplantation.
 Ichikawa T, Nakao K, Miyaaki H, et al 
Hepatol Res. 2009 Jul 13
 Abstract

Viral dynamics and pharmacokinetics in combined interferon alfa-2b and ribavirin therapy for patients infected with hepatitis C virus of genotype 1b and high pretreatment viral load.
 Tsubota A, Akuta N, Suzuki F, et al.
 Intervirology 2002;45(1):33-42
 Abstract
   
  Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin.
 Buti M, Sanchez-Avila F, Lurie Y, et al.
Hepatology 2002 Apr;35(4):930-6
 Abstract

     Adverse Reactions

 
A chronic subdural hematoma in a patient receiving combination therapy with pegylated interferon alfa-2b and ribavirin for chronic hepatitis C.
 Goto T, Ohshima S, Miura K,  et al
Intern Med. 2013;52(18):2057-60.
Abstract


Sustained exacerbation of cryoglobulinaemia-related vasculitis following treatment of hepatitis C with peginterferon alfa.
 Batisse D, Karmochkine M, Jacquot C, et al
Eur J Gastroenterol Hepatol. 2004 Jul;16(7):701-3.
 Abstract
 
Sudden hearing loss in patients with chronic hepatitis C treated with pegylated interferon/ribavirin.
 Formann E, Stauber R, Denk DM, et al.
 Am J Gastroenterol. 2004 May;99(5):873-7
 Abstract

Serious side-effects of interferon alfa and ribavirin combination
 Stransky J, Skrivankova J.
Vnitr Lek 2002 Jan;48(1):56-9
 Abstract
   
  Necrotizing cutaneous lesions complicating treatment with pegylated-interferon alfa in an HIV-infected patient.
 Bessis D, Charron A, Rouzier-Panis R, et al.
Eur J Dermatol 2002 Jan-Feb;12(1):99-102
 Abstract

     Efficacy

 

Phase 2 study of the combination of merimepodib with peginterferon-alpha2b, and ribavirin in nonresponders to previous therapy for chronic hepatitis C.
 Marcellin P, Horsmans Y, Nevens F, et al 
J Hepatol. 2007 Jun 21;
 Abstract
 
Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha.
 Shiffman ML, Salvatore J, Hubbard S, et al
Hepatology. 2007 Jun 8;
Abstract
 
Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection in HIV-Infected Patients.
Torriani FJ, Rodriguez-Torres M, Rockstroh, et al 
N Engl J Med. 2004 Jul 29;351(5):438-450.
 Abstract
 
A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance.
 Mauss S, Berger F, Goelz J, .et al
 Hepatology. 2004 Jul;40(1):120-4.
Abstract
 
Treatment of chronic hepatitis C infection with peginterferons plus ribavirin.
 Fried MW, Hadziyannis SJ.
 Semin Liver Dis. 2004 May;24 Suppl 2:47-54.
Abstract
 
Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C.
 Wong JB, Davis GL, McHutchison JG, et al 
Am J Gastroenterol. 2003 Nov;98(11):2354-62.
Abstract

Peginterferon vs. standard interferon in the treatment of chronic hepatitis C.
 Zaman A, Fennerty MB, Keeffe EB.
Aliment Pharmacol Ther. 2003 Oct;18(7):661-70.
 Abstract
   
  High sustained response rate in patients with histologically mild (low grade and stage) chronic hepatitis C infection. A randomized, double blind, placebo controlled trial of interferon alpha-2b with and without ribavirin.
 Verbaan HP, Widell HE, Bondeson TL    
 Eur J Gastroenterol Hepatol 2002 Jun;14(6):627-33
 Abstract
   
  Interferon alfa-2b plus ribavirin for chronic hepatitis C patients who have not responded to interferon monotherapy.
 Lo Iacono O, Castro A, Diago M, Moreno JA, et al.
Aliment Pharmacol Ther 2000 Apr;14(4):463-9
 Abstract
   
  Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C.
 de Ledinghen V, Trimoulet P, Winnock M, et al
J Hepatol 2002 May;36(5):672-80
 Abstract
   
  Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.
 Poynard T, McHutchison J, Manns M, et al
 Gastroenterology. 2002 May;122(5):1525-8.
Abstract
   
  Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin.
 McHutchison JG, Poynard T, Esteban-Mur R, et al.
Hepatology 2002 Mar;35(3):688-93
 Abstract
   
Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C.
 Scott LJ, Perry CM.
Drugs 2002;62(3):507-56
 Abstract

HIV/HCV

 
Real-world effectiveness of peginterferon α-2b plus ribavirin in a Canadian cohort of treatment-naïve chronic hepatitis C patients with genotypes 2 or 3: results of the PoWer and RediPEN studies.
 Marotta P, Bailey R, Elkashab M., et al
Eur J Clin Microbiol Infect Dis. 2016 Feb 6.
 Abstract
 

Efficacy and Safety of Pegylated Interferon-alpha2b Plus Ribavirin for the Treatment of Chronic Hepatitis C in HIV-Infected Patients.
 Santin M, Shaw E, Garcia MJ, et al 
AIDS Res Hum Retroviruses. 2006 Apr;22(4):315-2
Abstract
 
Serious ophthalmic pathology compromising vision in HCV/HIV co-infected patients treated with peginterferon alpha-2b and ribavirin.
 Farel C, Suzman DL, McLaughlin M, et al
 AIDS. 2004 Sep 3;18(13):1805-1809.
 Abstract

HIV coinfection does not compromise liver histological response to interferon therapy in patients with chronic hepatitis C.
 Di Martino V, Thevenot T, Boyer N, et al.
 AIDS 2002 Feb 15;16(3):441-5
 Abstract
   
  Necrotizing cutaneous lesions complicating treatment with pegylated-interferon alfa in an HIV-infected
patient.Bessis D, Charron A, Rouzier-Panis R, et al.
Eur J Dermatol 2002 Jan-Feb;12(1):99-102
 Abstract

Liver Fibrosis

  Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.
 Poynard T, McHutchison J, Manns M, et al.
Gastroenterology 2002 May;122(5):1303-13
 Abstract
 
A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation.
 Crippin JS, McCashland T, Terrault N, et al.
 Liver Transpl 2002 Apr;8(4):350-5
 Abstract

Liver Transplantation

  Pilot study of pegylated interferon alfa-2b and ribavirin for recurrent hepatitis C after liver transplantation.
 Mukherjee S, Rogge J, Weaver L, Schafer DF.et al 
Transplant Proc. 2003 Dec;35(8):3042-4.
Abstract

Dose Ranging Studies

  A dose-ranging study of pegylated interferon alfa-2b and ribavirinin chronic hepatitis C. The Hepatitis C Intervention Therapy Group.
 Glue P, Rouzier-Panis R, Raffanel C, et al.
 Hepatology 2000 Sep;32(3):647-53
 Abstract

HCV Drugs   Main New/Newsworthy Home Page

Peginterferon alfa-2b Main Page